Kajian Efek Samping Obat Kemoterapi Dosetaksel pada Kanker Payudara di RS Bhayangkara Kediri

https://doi.org/10.22146/jmpf.83782

Nunuk Wijayanti(1), Fita Rahmawati(2*), Pramugyono Pramugyono(3)

(1) Magister Farmasi Klinik, Fakultas Farmasi, Universitas Gadjah Mada, Yogyakarta
(2) Departemen Farmakologi dan Farmasi Klinik, Fakultas Farmasi, Universitas Gadjah Mada, Yogyakarta
(3) Departemen Onkologi, Rumah Sakit Bhayangkara, Kediri
(*) Corresponding Author

Abstract


Docetaxel is a chemotherapy drug for breast cancer. Chemotherapy can cause various side effects. This study aims to provide an overview of the side effects of non-hematological and hematological drugs from the use of docetaxel chemotherapy. The non-hematological side effects observed included dermatological disorders, endocrine and metabolic disturbances, and gastrointestinal-related disorders. While the observed hematological side effects included anemia, thrombocytopenia, leukopenia, and neutropenia. The study used a cross-sectional design with prospective data collection on 45 patients undergoing a docetaxel chemotherapy regimen with a dose of 100 mg/m2 at Bhayangkara Hospital, Kediri from January 2022 - March 2023. Data collection was carried out through medical records and then identification of drug side effects was carried out through pharmacist discussion with a consultant clinician in oncology. Data evaluation was carried out descriptively in the form of percentages. The most common non-hematological side effects were hair loss, which reached 80%, followed by skin hypersensitivity reactions, which reached 73.3%, and nail changes, which reached 48.9%. At the mild severity level (grade 1), skin hypersensitivity reactions were the highest at 73.3%, followed by hair loss at 64.4%. The most significant hematological side effect is anemia. Patients experienced anemia with grade 1 as much as 37.3% and 2.2% occurred in grade 2. The side effects of docetaxel that occurred in this study were overall in the mild (grade 1) and moderate (grade 2) categories. Most patients can still tolerate the symptoms of side effects that arise. Monitoring of drug side effects and prompt management of symptoms is necessary to reduce the severity and improve patient quality of life.


Keywords


dosetaksel; efek samping; kemoterapi

Full Text:

PDF


References

  1. WHO, 2020. International Agency for Research on Cancer: Indonesia. World Health Organization
  2. Kemkes, 2019. Penyakit Kanker di Indonesia Berada Pada Urutan 8 di Asia Tenggara dan Urutan 23 di Asia. URL:http://p2p.kemkes.go.id/penyakitkanker- di-indonesia-berada-pada-urutan-8-di-asia-tenggara-dan-urutan-23- di-asia/
  3. Farha NG, Kasi A. Docetaxel. StatPearls Publishing; 2022. Accessed March 10, 2023. https://www.ncbi.nlm.nih.gov/books/NBK537242/
  4. Brunton L, Knollmann B, Hilal-Dandan R. Goodman and Gilman’s The Pharmacological Basis of Therapeutics, 13th Edition. 13th edition. McGraw Hill / Medical; 2017.
  5. Ho MY, Mackey JR. Presentation and management of docetaxel-related adverse effects in patients with breast cancer. Cancer Manag Res. 2014;6:253-259. doi:10.2147/CMAR.S40601
  6. Rassy EE, Ghosn M, Farhat F, et al. Toxicities Associated with Docetaxel-Based Regimens in the Adjuvant Treatment of Early-Stage Breast Cancer: A Multicenter Prospective Real-Life Experience. Breast Care. 2018;13(2):119-123. doi:10.1159/000481339
  7. Stabellini N, Cullen J, Cao L, et al. Racial disparities in breast cancer treatment patterns and treatment related adverse events. Sci Rep. 2023;13(1):1233. doi:10.1038/s41598-023-27578-4
  8. Common Terminology Criteria for Adverse Events (CTCAE) v5.0. diakses 29/3/2023 jam 20.44 WIB. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5 _Quick_Reference_8.5x11.pdf
  9. Lexicomp®, 2022, Docetaxel (Lexi-Drugs Multinational). Diakses 20/7/2022 jam 16.48 WIB
  10. Sinulingga DI. Korelasi Short Form-36 dengan Skala Eastern Cooperative Oncology Group dalam Menilai Kualitas Hidup pada Pasien Limfoma Non Hodgkin yang Mendapat Kemoterapi Regimen Cyclophosphamide, Doxorubicin, Vincristine, dan Prednisone. Thesis. Universitas Sumatera Utara; 2014. Accessed June 14, 2023. https://repositori.usu.ac.id/handle/123456789/36684
  11. Angela, D., Djohan Ardiansyah, Desak Gede Agung Suprabawati, 2022. Hubungan intensitas nyeri dengan kualitas hidup pasien kanker payudara yang menjalani kemoterapi di PPLK RSUD Dr. Soetomo. Intisari Sains Medis 13(1): 109-116. DOI: 10.15562/ism.v13i1.1236
  12. Elmika,E., Mateus Sakundarno Adi. 2020. Gambaran Umur, dan Jenis Kelamin Pasien Kanker Payudara di RS Ibnu Sina Kota Makassar. Jurnal Penelitian Kesehatan Suara Forikes
  13. Panigoro, S. S., Amandito, R., Viryawan, C., Santoso, F., & Gautami, W. (2013). The Characteristics of Breast Cancer Patients in “ Dharmais ” Hospital National Cancer Center Jakarta Based on Occupational and Environmental Status. Indonesian Journal of Cancer, 7(2), 53–59.
  14. Sihombing, Faija, 2020. Hubungan Tingkat Pendidikan Formal dengan Tingkat Pengetahuan Wanita tentang Kanker Payudara. Jurnal Kebidanan (Nov 2020), Volume 12, Nomor 2
  15. Hutajulu SH, Prabandari YS, Bintoro BS, et al. Delays in the presentation and diagnosis of women with breast cancer in Yogyakarta, Indonesia: A retrospective observational study. PLOS ONE. 2022;17(1):e0262468. doi:10.1371/journal.pone.0262468
  16. Sharma N, Narayan S, Sharma R, Kapoor A, Kumar N, Nirban R. Association of comorbidities with breast cancer: An observational study. Trop J Med Res. 2015;19.
  17. Ng HS, Vitry A, Koczwara B, Roder D, McBride ML. Patterns of comorbidities in women with breast cancer: a Canadian population-based study. Cancer Causes Control CCC. 2019;30(9):931-941. doi:10.1007/s10552-019-01203-0
  18. Fan Y, Khan NH, Farhan Ali Khan M, et al. Association of Hypertension and Breast Cancer: Antihypertensive Drugs as an Effective Adjunctive in Breast Cancer Therapy. Cancer Manag Res. 2022;14:1323-1329. doi:10.2147/CMAR.S350854
  19. Han H, Guo W, Shi W, et al. Hypertension and breast cancer risk: a systematic review and meta-analysis. Sci Rep. 2017;7:44877. doi:10.1038/srep44877
  20. Utami W, Widayati K, Rahmawati F. Hubungan Penggunaan Antihipertensi Terhadap Rekurensi pada Pasien Kanker Payudara non Metastasis. Maj Farm. 2020;16(2):131-140. doi:10.22146/farmaseutik.v16i2.48603
  21. Zhao Y, Wang Q, Zhao X, Meng H, Yu J. Effect of antihypertensive drugs on breast cancer risk in female hypertensive patients: Evidence from observational studies. Clin Exp Hypertens N Y N 1993. 2018;40(1):22-27. doi:10.1080/10641963.2017.1288736
  22. Wulandari F, Widayati K, Rahmawati F. Hubungan Penyakit Diabetes Melitus dan Penggunaan Antidiabetes terhadap Rekurensi pada Pasien Kanker Payudara. J Manaj DAN PELAYANAN Farm J Manag Pharm Pract. 2019;9(4):294-302. doi:10.22146/jmpf.48069
  23. Zhao XB, Ren GS. Diabetes mellitus and prognosis in women with breast cancer: A systematic review and meta-analysis. Medicine (Baltimore). 2016;95(49):e5602. doi:10.1097/MD.0000000000005602
  24. Kemkes, 2013. Pedoman Teknis Pengendalian Kanker Payudara dan Kanker Leher Rahim. Direktorat PP & PL Direktorat Pengendalian Penyakit Tidak Menular
  25. Menkes, RI., 2018. Pedoman Nasional Pelayanan Kedokteran Tata Laksana Kanker Payudara
  26. Azam, F., Latif, M.F., Farooq, A., Tirmazy, S.H., AlShahrani, S., Bashir, S., dkk., 2019. Performance Status Assessment by Using ECOG (Eastern Cooperative Oncology Group) Score for Cancer Patients by Oncology Healthcare Professionals. Case Reports in Oncology, 12: 728–736.
  27. Sinaga ES, Ahmad RA, Shivalli S, Hutajulu SH. Age at diagnosis predicted survival outcome of female patients with breast cancer at a tertiary hospital in Yogyakarta, Indonesia. Pan Afr Med J. 2018;31:163. doi:10.11604/pamj.2018.31.163.17284
  28. Martín M, de la Torre-Montero JC, López-Tarruella S, et al. Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling. Breast Cancer Res Treat. 2018;171(3):627-634. doi:10.1007/s10549-018-4855-2
  29. Poi MJ, Berger M, Lustberg M, et al. Docetaxel-induced skin toxicities in breast cancer patients subsequent to paclitaxel shortage: a case series and literature review. Support Care Cancer Off J Multinatl Assoc Support Care Cancer. 2013;21(10):2679-2686. doi:10.1007/s00520-013-1842-3
  30. BC Cancer. Accessed March 22, 2023. http://www.bccancer.bc.ca/
  31. Alessandrini A, Starace M, Cerè G, Brandi N, Piraccini BM. Management and Outcome of Taxane-Induced Nail Side Effects: Experience of 79 Patients from a Single Centre. Skin Appendage Disord. 2019;5(5):276-282. doi:10.1159/000497824
  32. Choi SH, Lee JY, Lee SU, et al. A Case Report of Improvement of Docetaxel-induced Fluid Retention in a Patient with Advanced Gastric Cancer using Herbal Decoction, Modified Bangkihwangki-tang. J Korean Med. 2014;35(4):110-115. doi:10.13048/jkm.14049
  33. Dogan, S. E., Mizrak, D., Alkan, A., & Demirkazik, A. (2016). Docetaxel-induced pericardial effusion. Journal of Oncology Pharmacy Practice. https://doi.org/10.1177/1078155216643859
  34. Rescigno P, Lorenzo G di. The potential detrimental effect of corticosteroids in prostate cancer. Future Oncol. 2014;10(3):325-327. doi:10.2217/fon.13.270
  35. Adel N. Overview of chemotherapy-induced nausea and vomiting and evidence-based therapies. Am J Manag Care. 2017;23(14 Suppl):S259-S265
  36. van Eijk M, Vermunt MAC, van Werkhoven E, Wilthagen EA, Huitema ADR, Beijnen JH. The influence of docetaxel schedule on treatment tolerability and efficacy in patients with metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials. BMC Cancer. 2022;22(1):104. doi:10.1186/s12885-022-09196-x
  37. Sibaud V, Lebœuf NR, Roche H, et al. Dermatological adverse events with taxane chemotherapy. Eur J Dermatol EJD. 2016;26(5):427-443. Doi:10.1684/ejd.2016.283



DOI: https://doi.org/10.22146/jmpf.83782

Article Metrics

Abstract views : 3798 | views : 5371

Refbacks

  • There are currently no refbacks.


Copyright (c) 2023 JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice)

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

©Jurnal Manajemen dan Pelayanan Farmasi
Faculty of Pharmacy
Universitas Gadjah Mada
Creative Commons License
View My Stats